Medios AG expects significant increase in sales and earnings in 2018 financial year

DGAP-News: Medios AG / Key word(s): Forecast/Capital Increase

12.03.2018 / 11:29

The issuer is solely responsible for the content of this announcement.


Corporate News

Medios AG expects significant increase in sales and earnings in 2018 financial year

  • Forecasts for Group sales totalling 320 million euros and Group earnings before taxes (EBT) totalling 11 million euros
  • Planned growth of the patient-specific preparations segment through the expansion of the manufacturing facilities for non-cytostatic products
  • Intended takeover of substantial operating units of BerlinApotheke Schneider & Oleski oHG

Berlin, 12 March 2018 – Medios AG (‘Medios’), one of the leading Specialty Pharma Companies in Germany, expects a significant increase in sales and earnings in the 2018 financial year. Accordingly, the Management Board expects Group sales in the amount of around 320 million euros (IFRS) and Group earnings before taxes (EBT*) in the amount of around 11 million euros (IFRS)**. This represents considerable growth of 26 per cent and 37 per cent respectively compared to the preliminary figures already published for the 2017 financial year totalling 253 million euros (IFRS) and 8.0 million euros (IFRS) respectively.

The reasons for the expected increases in sales and earnings in the 2018 financial year are, in particular, the planned gaining of market shares as well as the further expansion of the partner network and the product offering. Additionally, the forecast takes into consideration the planned growth of the patient-specific preparations segment through the expansion of the manufacturing facilities for non-cytostatic products. For this purpose, the company intends to take over substantial operating units of BerlinApotheke Schneider & Oleski oHG (“BerlinApotheke”). The acquisition will be carried out without the expenditure of cash by means of a capital increase in kind in exchange for new shares issued to the contributing party, Mr Manfred Schneider, CEO of Medios AG and co-owner of BerlinApotheke. The new shares shall be introduced to trading on the regulated market of the Frankfurt Stock Exchange (General Standard). The required approval of the boards and the relevant authorities is expected over the coming weeks.

Matthias Gärtner, CFO of Medios AG: ‘With the takeover of the operating units and the expansion of the manufacturing facilities for non-cytostatic products, we can continue the expansion of our dynamically growing segment for patient-specific preparations, thereby taking us one step closer to achieving our goal of becoming the leading provider of Specialty Pharma solutions in Germany. The operating units are expected to be fully integrated into the Medios Group within the 2018 financial year and to begin production as of June 2018. Thereby, they will unfold their full potential from 2019 and then make significant contributions to EBT.’

* EBT is defined as net earnings before income taxes.
** Planned EBT for the 2018 financial year does not include the non-cash special effect from the share option plan (SOP), which was introduced based on the decision made by the 2017 annual general meeting and which serves the participation and incentivisation of executives. According to preliminary calculations, the special effect results in extraordinary expenses of some 1.25 million euros and is therefore approximately at the same level of the non-liquidity-related special item from the SOP in the 2017 financial year.

About Medios AG
Medios AG is one of the leading Specialty Pharma companies in Germany. As wholesaler for Specialty Pharma drugs and GMP-certified manufacturer of patient-specific medications, Medios covers substantial elements of the supply chain in this field and follows the highest international quality standards. Specialty Pharma drugs are, in particular, individualised infusions for patients with rare or chronic diseases like cancer, HIV and hepatitis. It is Medios’ aim to provide integrated solutions along the value chain to partners and clients, thereby ensuring an optimal pharmaceutical care for patients.

Medios AG is Germany’s first listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard) and Hamburg-Hannover Stock Exchange.

Contact
Kirchhoff Consult AG
Nikolaus Hammerschmidt
Borselstraße 20
22765 Hamburg
Germany
Telephone: +49 40 60918618
Fax: +49 40 60918660
E-mail: nikolaus.hammerschmidt@kirchhoff.de
www.kirchhoff.de

Disclaimer
This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification.


12.03.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Medios AG
Friedrichstraße 113a
10117 Berlin
Germany
Phone: +49 30 232 566 – 800
Fax: 030 / 8321 8377
E-mail: ir@medios.ag
Internet: www.medios.ag
ISIN: DE000A1MMCC8
WKN: A1MMCC
Listed: Regulated Market in Frankfurt (General Standard), Hamburg; Regulated Unofficial Market in Dusseldorf

 
End of News DGAP News Service

show this